Global Cancer Profiling Market
Historic Period: 2020–2024
Base Year: 2025
Estimated Year: 2026
Forecast Period: 2026–2036
Market Overview
The global Cancer Profiling Market is expanding rapidly due to growing adoption of precision oncology, increasing cancer incidence worldwide, and advancements in molecular diagnostics technologies. Cancer profiling enables identification of genetic mutations, protein expression patterns, and molecular signatures that guide targeted therapy selection and personalized treatment planning.
The shift from conventional histopathology toward multi-omics profiling platforms, liquid biopsy adoption, and AI-driven genomic interpretation is transforming the oncology diagnostics ecosystem. Pharmaceutical companies are increasingly collaborating with diagnostics providers to develop companion diagnostics, further accelerating market growth.
Market Segmentation Analysis
By Technology
1. Immunoassay
-
ELISA
-
Chemiluminescence Immunoassay (CLIA)
-
Multiplex Immunoassays
Insight: Widely used for protein biomarker detection and therapeutic monitoring.
2. Next-Generation Sequencing (NGS)
-
Whole Genome Sequencing
-
Whole Exome Sequencing
-
Targeted Gene Panels
-
RNA Sequencing
Insight: Dominant growth segment due to comprehensive mutation profiling capability.
3. Polymerase Chain Reaction (PCR)
-
Real-Time PCR
-
Digital PCR
-
Multiplex PCR
Insight: Cost-effective solution for mutation detection and minimal residual disease monitoring.
4. In Situ Hybridization (ISH)
-
FISH (Fluorescence In Situ Hybridization)
-
CISH (Chromogenic ISH)
Insight: Commonly used in HER2 and gene amplification detection.
5. Liquid Biopsy Technologies (New Segment)
-
Circulating Tumor DNA (ctDNA)
-
Circulating Tumor Cells (CTCs)
-
Exosome-Based Profiling
By Cancer Type
-
Breast Cancer
-
Lung Cancer
-
Colorectal Cancer
-
Prostate Cancer (New Segment)
-
Ovarian Cancer (New Segment)
-
Hematological Malignancies (New Segment)
By Biomarker Type
-
Genomic Biomarkers
-
Protein Biomarkers
-
Epigenetic Biomarkers (New Segment)
-
Transcriptomic Biomarkers (New Segment)
By Application
-
Research
-
Clinical Diagnostics
-
Companion Diagnostics (New Segment)
-
Drug Development & Clinical Trials
By End-User (New Segment)
-
Hospitals
-
Oncology Clinics
-
Diagnostic Laboratories
-
Academic & Research Institutes
-
Pharmaceutical & Biotechnology Companies
Regional Analysis
North America
North America holds the largest market share due to strong oncology research infrastructure, high adoption of NGS platforms, and extensive pharmaceutical collaborations. The United States leads in precision medicine implementation and companion diagnostic approvals.
Western Europe
Western Europe demonstrates steady growth driven by government-funded cancer screening programs and expanding genomic research initiatives.
Asia Pacific
Asia Pacific is projected to register the fastest growth during the forecast period. Rising cancer incidence, healthcare infrastructure expansion, and government precision medicine initiatives in China and Japan are key growth factors.
Eastern Europe
Growth supported by modernization of oncology diagnostic centers and increasing research funding.
Middle East
Gradual expansion due to healthcare investments and establishment of specialized oncology centers.
Rest of the World
Latin America and Africa show emerging potential driven by improving diagnostic accessibility.
Key Market Players
-
NeoGenomics Laboratories, Inc.
-
HTG Molecular Diagnostics, Inc.
-
Genomic Health, Inc.
-
Caris Life Sciences
-
NanoString Technologies, Inc.
-
Guardant Health, Inc.
-
F. Hoffmann-La Roche Ltd
-
Illumina, Inc.
-
Thermo Fisher Scientific Inc.
-
Agilent Technologies, Inc.
Porter’s Five Forces Analysis
1. Threat of New Entrants – Moderate
High R&D costs and regulatory approvals act as barriers; however, biotech startups focusing on liquid biopsy are emerging.
2. Bargaining Power of Suppliers – Moderate
Sequencing platform providers and reagent suppliers hold influence due to proprietary technologies.
3. Bargaining Power of Buyers – High
Hospitals and pharmaceutical companies negotiate pricing, especially for bulk genomic testing services.
4. Threat of Substitutes – Low
Traditional histopathology cannot fully substitute molecular profiling.
5. Competitive Rivalry – High
Intense competition driven by technological innovation, clinical validation studies, and companion diagnostic partnerships.
SWOT Analysis
Strengths
-
Enables personalized oncology treatment
-
Strong technological innovation pipeline
-
Growing integration with targeted therapies
Weaknesses
-
High test costs
-
Complex regulatory approval processes
-
Data interpretation challenges
Opportunities
-
Expansion of liquid biopsy testing
-
AI-driven genomic data analysis
-
Growth in emerging markets
-
Development of pan-cancer panels
Threats
-
Pricing pressures
-
Data privacy concerns
-
Reimbursement uncertainties
Market Drivers
-
Rising global cancer prevalence
-
Increasing demand for precision medicine
-
Advancements in sequencing technologies
-
Growing pharmaceutical investment in targeted therapies
-
Expansion of companion diagnostics
Market Challenges
-
High infrastructure costs
-
Skilled bioinformatics workforce shortage
-
Limited reimbursement in developing regions
-
Regulatory complexity
Trend Analysis
-
Growth in multi-omics profiling
-
Expansion of liquid biopsy adoption
-
AI-based genomic data interpretation
-
Increasing use of targeted gene panels
-
Integration with digital pathology platforms
Value Chain Analysis
Raw Material & Reagent Suppliers → Platform Manufacturers → Diagnostic Service Providers → Distributors → Hospitals & Research Institutes → Patients
Key value creation stages:
-
Biomarker discovery
-
Assay development & validation
-
Regulatory approval
-
Clinical integration & reporting
Competitive Landscape Overview
The Cancer Profiling market is moderately consolidated with established genomics leaders and emerging liquid biopsy innovators. Competitive differentiation is based on:
-
Panel comprehensiveness
-
Turnaround time
-
Clinical validation
-
Companion diagnostic partnerships
Strategic developments include mergers, AI integration, and expansion into emerging oncology markets.
Quick Strategic Recommendations
For Manufacturers
-
Invest in liquid biopsy and multi-omics platforms
-
Strengthen AI-powered data interpretation tools
-
Expand companion diagnostic collaborations
For Investors
-
Target companies focused on pan-cancer profiling
-
Explore Asia Pacific growth opportunities
For Healthcare Providers
-
Integrate cancer profiling into standard oncology pathways
-
Develop bioinformatics capabilities
For Pharmaceutical Companies
-
Partner with diagnostics firms for targeted therapy development
-
Expand clinical trial biomarker programs
TABLE OF CONTENTS
1 MARKET ABSTRACT
2 MARKET INTRODUCTION
2.1 MARKET SCOPE
2.2 MARKET PROPERTIES/ BEHAVIOR
2.3 KEY DEFINITIONS–CONTENT
3 QMI RESEARCH PRACTICE
3.1 RESEARCH PRACTICE
3.1.1 GLOBAL LEVEL ANALYSIS
3.1.2 COUNTRY LEVEL ANALYSIS
3.1.3 SUPPLY SIDE ANALYSIS
3.1.4 DEMAND SIDE ANALYSIS
3.1.5 TRIANGULATION
3.2 PRIMARY DATA
3.3 SECONDARY DATA
3.4 MARKET EVALUATION & FORECASTING METHODOLOGY
3.5 ASSUMPTIONS/ LIMITATIONS FOR THE STUDY
3.6 WHAT THIS STUDY PROVIDES
3.7 KEY QUESTIONS ANSWERED BY THIS REPORT
3.8 THIS STUDY IS INTENDED FOR
4 KEY RELATED DATA
4.1 COMPETITIVE POSITIONING
4.1.1 PRODUCT POSITIONING
4.1.2 REVENUE POSITIONING
4.1.3 REGIONAL REACH POSITIONING
4.2 VENDOR MATRIX
4.3 PATENTS
4.4 TECHNOLOGICAL ADVANCEMENTS
4.5 CUSTOMER ANALYSIS
5 IMPACT FACTOR ANALYSIS
5.1 MICRO ECONOMIC POINTERS
5.2 MACRO ECONOMIC POINTERS
5.3 PORTER’S FIVE FORCE MODEL/ PESTLE ANALYSIS/ VALUE CHAIN ANALYSIS
5.4 DRIVERS/RESTRAINTS/OPPORTUNITIES/CHALLENGES
6 MARKET DEVELOPMENT ANALYSIS
6.1 NEW PRODUCT DEVELOPMENT/ LAUNCH
6.2 MERGERS AND ACQUISITIONS
6.3 PARTNERSHIPS / AGREEMENTS/COLLABORATIONS
7 CANCER PROFILING MARKET, BY TECHNOLOGY
7.1 INTRODUCTION
7.2 MARKET SHARE ANALYSIS
7.3 IMMUNOASSAY
7.4 NGS
7.5 PCR
7.6 IN SITU HYBRIDIZATION
8 CANCER PROFILING MARKET, BY CANCER TYPE
8.1 INTRODUCTION
8.2 MARKET SHARE ANALYSIS
8.3 BREAST
8.4 LUNG
8.5 COLORECTAL
9 CANCER PROFILING MARKET, BY BIOMARKER TYPE
9.1 INTRODUCTION
9.2 MARKET SHARE ANALYSIS
9.3 GENOMIC BIOMARKERS
9.4 PROTEIN BIOMARKERS
10 CANCER PROFILING MARKET, BY APPLICATION
10.1 INTRODUCTION
10.2 MARKET SHARE ANALYSIS
10.3 RESEARCH
10.4 CLINICAL
11 CANCER PROFILING MARKET, REGIONAL ANALYSIS
11.1 INTRODUCTION
11.2 NORTH AMERICA CANCER PROFILING MARKET
11.2.1 NORTH AMERICA CANCER PROFILING MARKET, BY COUNTRY
11.2.1.1 US Cancer Profiling Market
11.2.1.2 Canada Cancer Profiling Market
11.2.1.3 Mexico Cancer Profiling Market
11.2.2 NORTH AMERICA CANCER PROFILING MARKET, BY TECHNOLOGY
11.2.3 NORTH AMERICA CANCER PROFILING MARKET, BY CANCER TYPE
11.2.4 NORTH AMERICA CANCER PROFILING MARKET, BY BIOMARKER TYPE
11.2.5 NORTH AMERICA CANCER PROFILING MARKET, BY APPLICATION
11.3 WESTERN EUROPE CANCER PROFILING MARKET
11.3.1 WESTERN EUROPE CANCER PROFILING MARKET, BY COUNTRY
11.3.1.1 Germany Cancer Profiling Market
11.3.1.2 UK Cancer Profiling Market
11.3.1.3 France Cancer Profiling Market
11.3.1.4 Italy Cancer Profiling Market
11.3.1.5 Spain Cancer Profiling Market
11.3.1.6 Rest of Western Europe Cancer Profiling Market
11.3.2 WESTERN EUROPE CANCER PROFILING MARKET, BY TECHNOLOGY
11.3.3 WESTERN EUROPE CANCER PROFILING MARKET, BY CANCER TYPE
11.3.4 WESTERN EUROPE CANCER PROFILING MARKET, BY BIOMARKER TYPE
11.3.5 WESTERN EUROPE CANCER PROFILING MARKET, BY APPLICATION
11.4 EASTERN EUROPE CANCER PROFILING MARKET
11.4.1 EASTERN EUROPE CANCER PROFILING MARKET, BY COUNTRY
11.4.1.1 Russia Cancer Profiling Market
11.4.1.2 Turkey Cancer Profiling Market
11.4.1.3 Rest of Eastern Europe Cancer Profiling Market
11.4.2 EASTERN EUROPE CANCER PROFILING MARKET, BY TECHNOLOGY
11.4.3 EASTERN EUROPE CANCER PROFILING MARKET, BY CANCER TYPE
11.4.4 EASTERN EUROPE CANCER PROFILING MARKET, BY BIOMARKER TYPE
11.4.5 EASTERN EUROPE CANCER PROFILING MARKET, BY APPLICATION
11.5 ASIA PACIFIC CANCER PROFILING MARKET
11.5.1 ASIA PACIFIC CANCER PROFILING MARKET, BY COUNTRY
11.5.1.1 China Cancer Profiling Market
11.5.1.2 Japan Cancer Profiling Market
11.5.1.3 India Cancer Profiling Market
11.5.1.4 South Korea Cancer Profiling Market
11.5.1.5 Australia Cancer Profiling Market
11.5.1.6 Taiwan Cancer Profiling Market
11.5.1.7 Malaysia Cancer Profiling Market
11.5.1.8 Indonesia Cancer Profiling Market
11.5.1.10 Rest of Asia Pacific Cancer Profiling Market
11.5.2 ASIA PACIFIC CANCER PROFILING MARKET, BY TECHNOLOGY
11.5.3 ASIA PACIFIC CANCER PROFILING MARKET, BY CANCER TYPE
11.5.4 ASIA PACIFIC CANCER PROFILING MARKET, BY BIOMARKER TYPE
11.5.5 ASIA PACIFIC CANCER PROFILING MARKET, BY APPLICATION
11.6 MIDDLE EAST CANCER PROFILING MARKET
11.6.1 MIDDLE EAST CANCER PROFILING MARKET, BY COUNTRY
11.6.1.1 UAE Cancer Profiling Market
11.6.1.2 Saudi Arabia Cancer Profiling Market
11.6.1.3 Qatar Cancer Profiling Market
11.6.1.4 Iran Cancer Profiling Market
11.6.1.5 Rest of Middle East Cancer Profiling Market
11.6.2 MIDDLE EAST CANCER PROFILING MARKET, BY TECHNOLOGY
11.6.3 MIDDLE EAST CANCER PROFILING MARKET, BY CANCER TYPE
11.6.4 MIDDLE EAST CANCER PROFILING MARKET, BY BIOMARKER TYPE
11.6.5 MIDDLE EAST CANCER PROFILING MARKET, BY APPLICATION
11.7 REST OF THE WORLD CANCER PROFILING MARKET
11.7.1 REST OF THE WORLD CANCER PROFILING MARKET, BY REGION
11.7.1.1 South America (Brazil, Argentina, Colombia, Others) Cancer Profiling Market
11.7.1.2 Africa (Nigeria, South Africa, Others) Cancer Profiling Market
11.7.2 REST OF THE WORLD CANCER PROFILING MARKET, BY TECHNOLOGY
11.7.3 REST OF THE WORLD CANCER PROFILING MARKET, BY CANCER TYPE
11.7.4 REST OF THE WORLD CANCER PROFILING MARKET, BY BIOMARKER TYPE
11.7.5 REST OF THE WORLD CANCER PROFILING MARKET, BY APPLICATION
12 CANCER PROFILING MARKET, COMPANY ANALYSIS
12.1 STERIS
12.1.1 FINANCIAL OVERVIEW
12.1.2 PRODUCT/SOLUTION OVERVIEW
12.1.3 SWOT ANALYSIS
12.1.4 KEY DEVELOPMENTS
12.2 ECOLAB, INC.
12.3 TOMI ENVIRONMENTAL SOLUTIONS, INC.
12.4 JCE BIOTECHNOLOGY
12.5 FEDEGARI AUTOCLAVI SPA
10.6 ZHEJIANG TAILIN BIOENGINEERING CO.
*Financials and Details May Not be Included in Case of Privately Held Company
13 CANCER PROFILING MARKET: CONCLUSION
13.1 CANCER PROFILING MARKET SNAPSHOT
13.2 CANCER PROFILING MARKET PROSPECTS- BY TECHNOLOGY
13.3 CANCER PROFILING MARKET PROSPECTS- BY CANCER TYPE
13.4 CANCER PROFILING MARKET PROSPECTS- BY BIOMAKER TYPE
13.5 CANCER PROFILING MARKET PROSPECTS- BY APPLICATION
14 APPENDIX
14.1 LIST OF ABBREVIATION
14.2 ADDITIONAL DEVELOPMENTS
14.3 RELATED REPORTS
Market Segmentation Analysis
By Technology
1. Immunoassay
-
ELISA
-
Chemiluminescence Immunoassay (CLIA)
-
Multiplex Immunoassays
Insight: Widely used for protein biomarker detection and therapeutic monitoring.
2. Next-Generation Sequencing (NGS)
-
Whole Genome Sequencing
-
Whole Exome Sequencing
-
Targeted Gene Panels
-
RNA Sequencing
Insight: Dominant growth segment due to comprehensive mutation profiling capability.
3. Polymerase Chain Reaction (PCR)
-
Real-Time PCR
-
Digital PCR
-
Multiplex PCR
Insight: Cost-effective solution for mutation detection and minimal residual disease monitoring.
4. In Situ Hybridization (ISH)
-
FISH (Fluorescence In Situ Hybridization)
-
CISH (Chromogenic ISH)
Insight: Commonly used in HER2 and gene amplification detection.
5. Liquid Biopsy Technologies (New Segment)
-
Circulating Tumor DNA (ctDNA)
-
Circulating Tumor Cells (CTCs)
-
Exosome-Based Profiling
By Cancer Type
-
Breast Cancer
-
Lung Cancer
-
Colorectal Cancer
-
Prostate Cancer (New Segment)
-
Ovarian Cancer (New Segment)
-
Hematological Malignancies (New Segment)
By Biomarker Type
-
Genomic Biomarkers
-
Protein Biomarkers
-
Epigenetic Biomarkers (New Segment)
-
Transcriptomic Biomarkers (New Segment)
By Application
-
Research
-
Clinical Diagnostics
-
Companion Diagnostics (New Segment)
-
Drug Development & Clinical Trials
By End-User (New Segment)
-
Hospitals
-
Oncology Clinics
-
Diagnostic Laboratories
-
Academic & Research Institutes
-
Pharmaceutical & Biotechnology Companies
